Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/28087
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWirach Maek-A-nantawaten_US
dc.contributor.authorBenjaluck Phonraten_US
dc.contributor.authorJittima Dhitavaten_US
dc.contributor.authorSupa Naksrisooken_US
dc.contributor.authorRungrapat Muanaumen_US
dc.contributor.authorVatcharachai Ngamdeeen_US
dc.contributor.authorPunnee Pitisuttithumen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-09-13T07:01:15Z-
dc.date.available2018-09-13T07:01:15Z-
dc.date.issued2009-05-01en_US
dc.identifier.citationSoutheast Asian Journal of Tropical Medicine and Public Health. Vol.40, No.3 (2009), 494-501en_US
dc.identifier.issn01251562en_US
dc.identifier.other2-s2.0-67650133578en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=67650133578&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/28087-
dc.description.abstractComplementary remedies represent a potential alternative treatment for chronic diseases, including HIV/AIDS cases not meeting criteria for using highly active antiretroviral therapy (HAART). This study evaluated the safety and efficacy of CKBM-A01, a Chinese herbal medicine, and patient quality of life (QoL). Asymptomatic HIV patients with CD4 counts of 250-350 cells/μl were recruited into this openlabeled trial. Liquid CKBM-A01 was prescribed for a 36-week period. Study participants recorded all symptoms themselves on diary cards. Study parameters, including CD4 cell counts, HIV viral loads, and blood chemistry, were periodically monitored and questionnaires were used to assess QoL and to help with risk reduction. Eighteen volunteers, mean age (± SD) 32.07 (±6.88) years, had a median (interquartile range, IQR) baseline CD4 count of 292 (268.50-338.25) cells/Μl. No serious drug-related adverse events due to CKBM-A01 were detected during the study. Intermittent diarrhea was reported in 55.6%, weakness or skin rash/itching in 50%, and increased bowel movement in 33.7%. No significant changes in log viral load or CD4 cell counts were observed at the end of the study. Most of the volunteers (72.2%) expressed satisfaction with CKBM-A01 and had a positive perception. Common colds and nasal symptoms were significantly lower during treatment (ρ=0.019). CKBM-A01 appeared to be safe but gave no significant improvement in QoL in asymptomatic HIV patients, and gave no significant improvement in the treatment of HIV based on CD4 cell counts and viral loads.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=67650133578&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleSafety and efficacy of CKBM-A01, a Chinese herbal medicine, among Asymptomatic HIV patientsen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.